Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 10, 2004, Pages 2606-2614

  Budde, Klemens ^a   Neumayer, Hans Hellmut ^a   Lehne, Gustav ^b   Winkler, Michael ^c   Hauser, Ingeborg Anni ^d   Lison, Arno ^e   Fritsche, Lutz ^a   Soulillou, Jean Paul ^f   Fauchald, Per ^b   Dantal, Jaques ^f   Lerat, L ^g   Nordal, K ^g   Muller L ^g   Brunkhost, R ^g   Renders, L ^g   Burckhardt, K ^g   Schreiber, M ^g   Wullstein, H G ^g   Schotschel R ^g   Charpentier, B ^g   McMaster, P ^g   Schmidt, Albrecht Georg ^h   Jappe, Annette ^h   Cambon, Nathalie ^h   Von Fellenberg, Janet ^h   Paradis, Khazal ^h   Dingemanse, Silke Appel ^h   Legay, Francois ^h   Gerbeau, Christophe ^g   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Riskshospitalet   (Norway)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Unviersitatsklinikum Frankfurt   (Germany)

^e Zentralkrankenhaus   (Germany)

^f HÔTEL DIEU   (France)

^g Novartis ^*

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Everolimus; Pharmacodynamics; Pharmacokinetics; Renal transplantation

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; PLACEBO; PREDNISONE; SULFAMETHOXAZOLE;

ADULT; AGED; ANEMIA; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPISTAXIS; ERYTHROCYTE SEDIMENTATION RATE; EXTRASYSTOLE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTESTINE OBSTRUCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TABLET; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

EID: 5444267283     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh322     Document Type: Article

References (20)

1. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903-1917
2. Neumayer H-H, Paradis K, Korn A et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694-703
3. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Invest Drugs 2002; 11: 1845-1857
4. Schwarz C, Oberbauer R. The future role of target of rapamycin inhibitors in renal transplantation. Curr Opin Urol 2002; 12: 109-113
5. Schuurman HJ, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32-35
6. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737-742
7. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150-159
8. Hausen B, Ikonen T, Briffa N et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ-RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69: 76-86
9. Nikolova Z, Hof A, Baumlin Y, Hof RP. Efficacy of SDZ RAD compared with CsA monotherapy and combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. Transplant Immunol 2001; 9: 43-49
10. Hausen B, Boeke K, Berry GJ, Christians U, Schuler W, Morris RE. Successful treatment of acute, ongoing rat lung allograft rejection with the novel macrolide immunosuppressant SDZ RAD. Ann ThoracSurg 2000; 69: 904-909
11. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998: 30: 2200-2203
12. Nashan B. The role of certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc 2001; 33: 3215-3220
13. Kahan BD, Wong R, Carter C et al. A phase1 study of a 4-week course of SDZ-RAD (RAD) in quiescent cylosporine-prednisone-treated renal transplant recipients. Transplantation 1999; 67: 1100-1106
14. Murgia MG, Jordan S, Kahan BD. The side-effect profile of sirolimus: a phase 1 study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209-216
15. Groth CG, Backman L, Morales JM et al Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporin. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042
16. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
17. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998; 31: 345-351
18. Kovarik JM, Kaplan B, Tedesco Silva H et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920-925
19. Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247-254
20. Kovarik JM, Kahan BD, Kaplan B et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69: 48-56